Announcements

2 July 2025
Biomedicines | Hot Papers in the “Cancer Biology and Oncology” Section

The “Cancer Biology and Oncology” Section publishes reviews and original peer-reviewed papers of a high scientific standard, covering all aspects of innovative cancer therapies. Papers aim to uncover novel therapeutic approaches toward overcoming conventional anticancer drug resistance and a better understanding of the interrelations between cancer and metabolism in addition to a better understanding of the tumor and its microenvironment, along with the discovery of novel diagnostic and prognostic makers. Topics include but are not limited to in vitro and in vivo cancer therapeutic responses, targeted therapies (including metabolism and immunotherapy, such as those involving CAR-T cells), identification of novel therapeutic targets, and evaluation of novel diagnosis and prognosis markers and the assessment of their impact on morphological, phenotypical, and molecular classifications.

1. “Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms”
by Theodoros Sidiropoulos, Nikolas Dovrolis, Hector Katifelis, Nikolaos V. Michalopoulos, Panagiotis Kokoropoulos, Nikolaos Arkadopoulos and Maria Gazouli
Biomedicines 2024, 12(5), 1040; https://doi.org/10.3390/biomedicines12051040
Available online: https://www.mdpi.com/2227-9059/12/5/1040

2. “IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia”
by Jonathan Paolino, Harrison K. Tsai, Marian H. Harris and Yana Pikman
Biomedicines 2024, 12(1), 89; https://doi.org/10.3390/biomedicines12010089
Available online: https://www.mdpi.com/2227-9059/12/1/89

3. “miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression”
by Francesca Maria Orlandella, Esther Imperlini, Katia Pane, Neila Luciano, Mariantonia Braile, Anna Elisa De Stefano, Paola Lucia Chiara Iervolino, Alessandro Ruocco, Stefania Orrù, Monica Franzese et al.
Biomedicines 2024, 12(3), 658. https://doi.org/10.3390/biomedicines12030658
Available online: https://www.mdpi.com/2227-9059/12/3/658

4. “Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer”
by Hänel W. Eberly, Bao Y. Sciscent, F. Jeffrey Lorenz, Eleni M. Rettig and Neerav Goyal
Biomedicines 2024, 12(2), 415; https://doi.org/10.3390/biomedicines12020415
Available online: https://www.mdpi.com/2227-9059/12/2/415

5. “Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes”
by Aleksandra Ciarka, Michał Piątek, Rafał Pęksa, Michał Kunc and Elżbieta Senkus
Biomedicines 2024, 12(4), 763; https://doi.org/10.3390/biomedicines12040763
Available online: https://www.mdpi.com/2227-9059/12/4/763

6. “Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging”
by Rita Saúde-Conde, Ayça Arçay Öztürk, Kosta Stosic, Oier Azurmendi Senar, Julie Navez, Christelle Bouchart, Tatjana Arsenijevic, Patrick Flamen and Jean-Luc Van Laethem
Biomedicines 2024, 12(3), 591; https://doi.org/10.3390/biomedicines12030591
Available online: https://www.mdpi.com/2227-9059/12/3/591

7. “Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification”
by Tomohiro Chiba
Biomedicines 2024, 12(4), 712; https://doi.org/10.3390/biomedicines12040712
Available online: https://www.mdpi.com/2227-9059/12/4/712

8. “Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer”
by Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, Giovanna Masci, Chiara Miggiano, Mariangela Gaudio, Chiara Benvenuti, Flavia Jacobs, Riccardo Gerosa, Armando Santoro et al.
Biomedicines 2024, 12(3), 500; https://doi.org/10.3390/biomedicines12030500
Available online: https://www.mdpi.com/2227-9059/12/3/500

9. “Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer”
by David K. Lau, Jack P. Collin and John M. Mariadason
Biomedicines 2024, 12(5), 1117; https://doi.org/10.3390/biomedicines12051117
Available online: https://www.mdpi.com/2227-9059/12/5/1117

10. “Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment”
by Agata M.Gawel, Anna Betkowska, Ewa Gajda, Marlena Godlewska and Damian Gawel
Biomedicines 2024, 12(8), 1822; https://doi.org/10.3390/biomedicines12081822
Available online: https://www.mdpi.com/2227-9059/12/8/1822

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:

This Section is currently open for submissions. Papers may be submitted via the following link:

https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:

If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

2 July 2025
Biomedicines | Hot Papers in the “Endocrinology and Metabolism Research” Section

The “Endocrinology and Metabolism Research” Section publishes original and innovative scientific papers, as well as comprehensive review papers. In this context, we are pleased to feature some recently published papers in Biomedicines (ISSN: 2227-9059) on gene regulation, cell biology, signaling, mutations, growth factors, cytokines, hormone receptors, hormone action and regulation, developmental endocrinology, genetic endocrinology, endocrine diseases (diabetes, obesity, osteoporosis, hyperthyroidism, etc.), and metabolic diseases, which will provide valuable insights into this exciting field.

1. “Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond”
by Allison Soto, Colby Spongberg, Alessandro Martinino and Francesco Giovinazzo
Biomedicines 2024, 12(2), 397; https://doi.org/10.3390/biomedicines12020397
Available online: https://www.mdpi.com/2227-9059/12/2/397

2. “The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance”
by Petru Baneu, Cristina Văcărescu, Simona-Ruxanda Drăgan, Liviu Cirin, Alexandra-Iulia Lazăr-Höcher, Andreea Cozgarea, Adelina-Andreea Faur-Grigori, Simina Crișan, Dan Gaiță, Constantin-Tudor Luca et al.
Biomedicines 2024, 12(7), 1493; https://doi.org/10.3390/biomedicines12071493
Available online: https://www.mdpi.com/2227-9059/12/7/1493

3. “Novel Factors Regulating Proliferation, Migration, and Differentiation of Fibroblasts, Keratinocytes, and Vascular Smooth Muscle Cells during Wound Healing”
by Jacob Smith and Vikrant Rai
Biomedicines 2024, 12(9), 1939; https://doi.org/10.3390/biomedicines12091939
Available online: https://www.mdpi.com/2227-9059/12/9/1939

4. “The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?”
by Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, Panagiotis Theofilis, Marios Sagris, Theocharis Koufakis, Panayotis K. Vlachakis, Imran Rashid Rangraze, Mohamed El Tanani, Konstantinos Tsioufis et al. 
Biomedicines 2024, 12(9), 2112; https://doi.org/10.3390/biomedicines12092112
Available online: https://www.mdpi.com/2227-9059/12/9/2112

5. “Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease”
by Muna A. Adem, Boris Decourt and Marwan N. Sabbagh
Biomedicines 2024, 12(1), 99; https://doi.org/10.3390/biomedicines12010099
Available online: https://www.mdpi.com/2227-9059/12/1/99

6. “NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics”
by Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, Maria Paraskevi Panoilia, Anna Daskou, Theodora Stratigou, Irene Karampela, Dimitrios Tsilingiris and Maria Dalamaga
Biomedicines 2024, 12(4), 826; https://doi.org/10.3390/biomedicines12040826
Available online: https://www.mdpi.com/2227-9059/12/4/826

7. “Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications”
by Laura Hölzen, Bernd Schultes, Bernd Schultes and Svenja Meyhöfer
Biomedicines 2024, 12(2), 391; https://doi.org/10.3390/biomedicines12020391
Available online: https://www.mdpi.com/2227-9059/12/2/391

8. “Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction?”
by Akila Lara Oliveira, Mariana Gonçalves de Oliveira, Fabíola Zakia Mónica and Edson Antunes
Biomedicines 2024, 12(5), 939; https://doi.org/10.3390/biomedicines12050939
Available online: https://www.mdpi.com/2227-9059/12/5/939

9. “The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review”
by Eva Zikou, Chrysi Koliaki and Konstantinos Makrilakis
Biomedicines 2024, 12(8), 1871; https://doi.org/10.3390/biomedicines12081871
Available online: https://www.mdpi.com/2227-9059/12/8/1871

10. “Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s”
by Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović and Antonio Simone Laganà
Biomedicines 2024, 12(3), 653; https://doi.org/10.3390/biomedicines12030653
Available online: https://www.mdpi.com/2227-9059/12/3/653

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link:
https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

2 July 2025
Biomedicines | Hot Papers in the “Biomedical Engineering and Materials” Section

The “Biomedical Engineering and Materials” Section publishes reviews and original peer-reviewed papers which aim to cover studies of the preparation, performance, and evaluation of biomaterials; the chemical, physical, toxicological, and mechanical behavior of materials in physiological environments; and the response of blood and tissues to biomaterials. It also covers biomedical engineering approaches as solutions to clinical practice. In this context, we are pleased to feature some recently published papers on biomedical engineering and materials in Biomedicines (ISSN: 2227-9059), which will provide valuable insights into this exciting field.

1. “Artificial Intelligence in Pediatric Emergency Medicine: Applications, Challenges, and Future Perspectives”
by Lorenzo Di Sarno, Anya Caroselli, Giovanna Tonin, Benedetta Graglia, Valeria Pansini, Francesco Andrea Causio, Antonio Gatto and Antonio Chiaretti
Biomedicines 2024, 12(6), 1220; https://doi.org/10.3390/biomedicines12061220
Available online: https://www.mdpi.com/2227-9059/12/6/1220

2. “Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients”
by Armin Hakkak Moghadam Torbati, Sara Pellegrino, Rosa Fonti, Rocco Morra, Sabino De Placido and Silvana Del Vecchio
Biomedicines 2024, 12(3), 472; https://doi.org/10.3390/biomedicines12030472
Available online: https://www.mdpi.com/2227-9059/12/3/472

3. “Design of Alginate/Gelatin Hydrogels for Biomedical Applications: Fine-Tuning Osteogenesis in Dental Pulp Stem Cells While Preserving Other Cell Behaviors”
by Zied Ferjaoui, Roberto López-Muñoz, Soheil Akbari, Fatiha Chandad, Diego Mantovani, Mahmoud Rouabhia and Roberto D. Fanganiello
Biomedicines 2024, 12(7), 1510; https://doi.org/10.3390/biomedicines12071510
Available online: https://www.mdpi.com/2227-9059/12/7/1510

4. “Improving Surgical Scene Semantic Segmentation through a Deep Learning Architecture with Attention to Class Imbalance”
by Claudio Urrea, Yainet Garcia-Garcia and John Kern
Biomedicines 2024, 12(6), 1309; https://doi.org/10.3390/biomedicines12061309
Available online: https://www.mdpi.com/2227-9059/12/6/1309

5. “A Combined Computational and Experimental Analysis of PLA and PCL Hybrid Nanocomposites 3D Printed Scaffolds for Bone Regeneration”
by Spyros V. Kallivokas, Lykourgos C. Kontaxis, Spyridon Psarras, Maria Roumpi, Ourania Ntousi, Ioannis Kakkos, Despina Deligianni, George K. Matsopoulos, Dimitrios I. Fotiadis and Vassilis Kostopoulos
Biomedicines 2024, 12(2), 261; https://doi.org/10.3390/biomedicines12020261
Available online: https://www.mdpi.com/2227-9059/12/2/261

6. “A Comprehensive Review of Muscle–Tendon Junction: Structure, Function, Injury and Repair”
by Siqi Tong, Yuzhi Sun, Baian Kuang, Mingyue Wang, Zhixuan Chen, Wei Zhang and Jialin Chen
Biomedicines 2024, 12(2), 423; https://doi.org/10.3390/biomedicines12020423
Available online: https://www.mdpi.com/2227-9059/12/2/423

7. “In Vivo Osteogenic and Angiogenic Properties of a 3D-Printed Isosorbide-Based Gyroid Scaffold Manufactured via Digital Light Processing”
by Fiona Verisqa, Jeong-Hui Park, Nandin Mandakhbayar, Jae-Ryung Cha, Linh Nguyen, Hae-Won Kim and Jonathan C. Knowles
Biomedicines 2024, 12(3), 609; https://doi.org/10.3390/biomedicines12030609
Available online: https://www.mdpi.com/2227-9059/12/3/609

8. “Proposal and Definition of an Intelligent Clinical Decision Support System Applied to the Prediction of Dyspnea after 12 Months of an Acute Episode of COVID-19”
by Manuel Casal-Guisande, Alberto Comesaña-Campos, Marta Núñez-Fernández, María Torres-Durán and Alberto Fernández-Villar
Biomedicines 2024, 12(4), 854; https://doi.org/10.3390/biomedicines12040854
Available online: https://www.mdpi.com/2227-9059/12/4/854

9. “Mechanical and Material Analysis of 3D-Printed Temporary Materials for Implant Reconstructions—A Pilot Study”
by Adam Nowicki, Karolina Osypko, Adam Kurzawa, Maciej Roszak, Karina Krawiec and Dariusz Pyka
Biomedicines 2024, 12(4), 870; https://doi.org/10.3390/biomedicines12040870
Available online: https://www.mdpi.com/2227-9059/12/4/870

10. “Machine Learning for COVID-19 Determination Using Surface-Enhanced Raman Spectroscopy”
by Tomasz R. Szymborski, Sylwia M. Berus, Ariadna B. Nowicka, Grzegorz Słowiński and Agnieszka Kamińska
Biomedicines 2024, 12(1), 167; https://doi.org/10.3390/biomedicines12010167
Available online: https://www.mdpi.com/2227-9059/12/1/167

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: 
https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

2 July 2025
Biomedicines | Hot Papers in the “Neurobiology and Clinical Neuroscience” Section

This Section publishes reviews and original peer-reviewed papers of a high scientific level covering all aspects of the treatment of neurobiology and neurologic diseases. Topics include but are not limited to neurogenesis, neuroplasticity, neuropharmacology and neurotherapeutics, in vitro and in vivo responses to neurological diseases, identification of therapeutic targets, evaluation of diagnostic markers, and assessment of therapies for neurological disorders.

1. “The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress”
by Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, László Vécsei and Masaru Tanaka
Biomedicines 2024, 12(2), 448; https://doi.org/10.3390/biomedicines12020448
Available online: https://www.mdpi.com/2227-9059/12/2/448

2. “Current and Future Applications of Arterial Spin Labeling MRI in Cerebral Arteriovenous Malformations”
by Matteo De Simone, Marco Maria Fontanella, Anis Choucha, Karl Schaller, Paolo Machi, Giuseppe Lanzino, Philippe Bijlenga, Felix T. Kurz, Karl-Olof Lövblad and Lucio De Maria
Biomedicines 2024, 12(4), 753; https://doi.org/10.3390/biomedicines12040753
Available online: https://www.mdpi.com/2227-9059/12/4/753

3. “Inflammation in the Peripheral Nervous System after Injury”
by Dandan Gu, Yiming Xia, Zihan Ding, Jiaxi Qian, Xi Gu, Huiyuan Bai, Maorong Jiang and Dengbing Yao
Biomedicines 2024, 12(6), 1256; https://doi.org/10.3390/biomedicines12061256
Available online: https://www.mdpi.com/2227-9059/12/6/1256

4. “Molecular Mechanisms of Ischemic Stroke: A Review Integrating Clinical Imaging and Therapeutic Perspectives”
by Sana Rehman, Arsalan Nadeem, Umar Akram, Abeer Sarwar, Ammara Quraishi, Hina Siddiqui, Muhammad Abdullah Javed Malik, Mehreen Nabi, Ihtisham Ul Haq, Andrew Cho et al.
Biomedicines 2024, 12(4), 812; https://doi.org/10.3390/biomedicines12040812
Available online: https://www.mdpi.com/2227-9059/12/4/812

5. “Traumatic Brain Injury and Neuromodulation Techniques in Rehabilitation: A Scoping Review”
by Andrea Calderone, Davide Cardile, Antonio Gangemi, Rosaria De Luca, Angelo Quartarone, Francesco Corallo and Rocco Salvatore Calabrò
Biomedicines 2024, 12(2), 438; https://doi.org/10.3390/biomedicines12020438
Available online: https://www.mdpi.com/2227-9059/12/2/438

6. “Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management”
by Maria Leonor Ferreira do Couto, Sara Fonseca and Daniel Humberto Pozza
Biomedicines 2024, 12(4), 729; https://doi.org/10.3390/biomedicines12040729
Available online: https://www.mdpi.com/2227-9059/12/4/729

7. “Neurotrauma—From Injury to Repair: Clinical Perspectives, Cellular Mechanisms and Promoting Regeneration of the Injured Brain and Spinal Cord”
by Andrew R. Stevens, Antonio Belli and Zubair Ahmed
Biomedicines 2024, 12(3), 643; https://doi.org/10.3390/biomedicines12030643
Available online: https://www.mdpi.com/2227-9059/12/3/643

8. “Role of Microbiota-Derived Hydrogen Sulfide (H2S) in Modulating the Gut–Brain Axis: Implications for Alzheimer’s and Parkinson’s Disease Pathogenesis”
by Constantin Munteanu, Gelu Onose, Mariana Rotariu, Mădălina Poștaru, Marius Turnea and Anca Irina Galaction
Biomedicines 2024, 12(12), 2670; https://doi.org/10.3390/biomedicines12122670
Available online: https://www.mdpi.com/2227-9059/12/12/2670

9. “Diabetic Neuropathic Pain: Directions for Exploring Treatments”
by Yuchen Chen and Xue-Jun Song
Biomedicines 2024, 12(3), 589; https://doi.org/10.3390/biomedicines12030589
Available online: https://www.mdpi.com/2227-9059/12/3/589

10. “Transcutaneous Auricular Vagus Nerve Stimulation to Improve Emotional State”
by Ainara Aranberri Ruiz
Biomedicines 2024, 12(2), 407; https://doi.org/10.3390/biomedicines12020407
Available online: https://www.mdpi.com/2227-9059/12/2/407

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

2 July 2025
Biomedicines | Hot Papers in the “Microbiology in Human Health and Disease” Section

Microorganisms are an essential part of life on Earth, playing an important role in almost every natural cycle. The “Microbiology in Human Health and Disease” Section focuses on microbiology in human health and diseases, including infectious diseases, the interaction between pathogenic microorganisms and hosts, bacteriology, mycology, virology, and parasitology. The point of view of the Section is that microorganisms and public health are closely intertwined and that advances in one area will have positive consequences on the other.

1. “Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia”
by Da Hyun Kang, Grace Hyun J. Kim, Sa-Beom Park, Song-I Lee, Jeong Suk Koh, Matthew S. Brown, Fereidoun Abtin, Michael F. McNitt-Gray, Jonathan G. Goldin and Jeong Seok Lee
Biomedicines 2024, 12(1), 120; https://doi.org/10.3390/biomedicines12010120
Available online: https://www.mdpi.com/2227-9059/12/1/120

2. “Microbiota Implications in Endocrine-Related Diseases: From Development to Novel Therapeutic Approaches”
by Vicente Javier Clemente-Suárez, Laura Redondo-Flórez, Alejandro Rubio-Zarapuz, Alexandra Martín-Rodríguez and José Francisco Tornero-Aguilera
Biomedicines 2024, 12(1), 221; https://doi.org/10.3390/biomedicines12010221
Available online: https://www.mdpi.com/2227-9059/12/1/221

3. “The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter”
by Miruna-Maria Apetroaei, Bruno Ștefan Velescu, Marina Ionela (Ilie) Nedea, Cristina Elena Dinu-Pîrvu, Doina Drăgănescu, Anca Ionela Fâcă, Denisa Ioana Udeanu and Andreea Letiția Arsene
Biomedicines 2024, 12(4), 915; https://doi.org/10.3390/biomedicines12040915
Available online: https://www.mdpi.com/2227-9059/12/4/915

4. “The Role of Gut Microbiota and Its Metabolites in Patients with Heart Failure”
by Krzysztof Cienkowski, Alicja Cienkowska, Karolina Kupczynska and Agata Bielecka-Dabrowa
Biomedicines 2024, 12(4), 894; https://doi.org/10.3390/biomedicines12040894
Available online: https://www.mdpi.com/2227-9059/12/4/894

5. “Rift Valley Fever Virus: An Overview of the Current Status of Diagnostics”
by Daniele Lapa, Silvia Pauciullo, Ida Ricci, Anna Rosa Garbuglia, Fabrizio Maggi, Maria Teresa Scicluna and Silvia Tofani
Biomedicines 2024, 12(3), 540; https://doi.org/10.3390/biomedicines12030540
Available online: https://www.mdpi.com/2227-9059/12/3/540

6. “Gut Permeability and Immune-Mediated Inflammation in Heart Failure”
by Maria Perticone, Simona Gigliotti, Ermal Shehaj, Raffaele Maio, Edoardo Suraci, Sofia Miceli, Francesco Andreozzi, Giovanni Matera and Francesco Perticone
Biomedicines 2024, 12(6), 1217; https://doi.org/10.3390/biomedicines12061217
Available online: https://www.mdpi.com/2227-9059/12/6/1217

7. “Skin Lesions Caused by HPV—A Comprehensive Review”
by Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog and Anca Huniadi
Biomedicines 2024, 12(9), 2098; https://doi.org/10.3390/biomedicines12092098
Available online: https://www.mdpi.com/2227-9059/12/9/2098

8. “Maternal Exposure to Endocrine-Disrupting Chemicals: Analysis of Their Impact on Infant Gut Microbiota Composition”
by Mirco Vacca, Francesco Maria Calabrese, Federica Loperfido, Beatrice Maccarini, Rosa Maria Cerbo, Eduardo Sommella, Emanuela Salviati, Luana Voto, Maria De Angelis, Gabriele Ceccarelli et al.
Biomedicines 2024, 12(1), 234; https://doi.org/10.3390/biomedicines12010234
Available online: https://www.mdpi.com/2227-9059/12/1/234

9. “Study of Periodontal Bacteria in Diabetic Wistar Rats: Assessing the Anti-Inflammatory Effects of Carvacrol and Magnolol Hydrogels”
by Georgiana Ioana Potra Cicalău, Olivia Andreea Marcu, Timea Claudia Ghitea, Gabriela Ciavoi, Raluca Cristina Iurcov, Corina Beiusanu, Daniela Florina Trifan, Laura Grațiela Vicaș and Mariana Ganea
Biomedicines 2024, 12(7), 1445; https://doi.org/10.3390/biomedicines12071445
Available online: https://www.mdpi.com/2227-9059/12/7/1445

10. “Characterization of the Outer Membrane Vesicles of Pseudomonas aeruginosa Exhibiting Growth Inhibition against Acinetobacter baumannii
by Jin-Woong Suh, Jae-Seong Kang, Jeong-Yeon Kim, Sun-Bean Kim, Young-Kyung Yoon and Jang-Wook Sohn
Biomedicines 2024, 12(3), 556; https://doi.org/10.3390/biomedicines12030556
Available online: https://www.mdpi.com/2227-9059/12/3/556

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines (ISSN: 2227-9059). We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines.

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit.

Biomedicines Editorial Office

2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s 2024 Impact Factor Highlights

For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.

While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.

“These results reflect the trust that the scholarly community places in MDPI”

MDPI’s 2024 Impact Factor Highlights

  • 298 MDPI journals received a Journal Impact Factor.
  • 60 journals earned their first-ever Impact Factor
    • To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
    • Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
  • 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
    • What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
  • 116 of our previously ranked journals increased their Impact Factor.
  • 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.

These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.

Open Access with Impact

As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.

Further Reading

If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.

You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.

Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.

Impactful Research

MDPI Journals See Continued Growth in 2024 CiteScore Results

Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.

2024 Highlights:

  • 322 MDPI journals received a CiteScore (up from 274 last year).
  • 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
  • 237 journals (85%) saw an increase in their CiteScore compared to last year.
  • 48 journals received a CiteScore for the first time.
  • 39 journals are now placed in the top 10% of their subject areas.

“This growth highlights our commitment to supporting open, trusted science”

What is CiteScore and how is it measured?

CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.

Why is this important?

These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.

Inside MDPI

Highlights from the MDPI USA Summit in Boston (5–6 June)

With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.

Why do we organize MDPI Summits?

These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:

  1. Share MDPI’s values, achievements, editorial practices, and local market collaborations.
  2. Collect feedback on MDPI operations and journal practices.
  3. Empower Chief Editors to confidently represent MDPI beyond the Summit.

While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.

About the Boston Summit

Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.

Agenda Highlights:

Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:

  • MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
  • AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
  • MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Panel Discussion – Stefan, Feichi, Giulia, Claudia
  • Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
  • Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)

MDPI & the USA: Facts and Figures

  • With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
  • In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
  • As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
  • As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
  • Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
  • MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.

A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.

Coming Together for Science

Highlights from the MDPI France Summit in Paris (12–13 June)

We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.

Why a France Summit?

We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.

“Our authors and editors very much enjoy working with us”

Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:

This is not accurate.

A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.

The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.

Summit Overview

Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.

Summit Feedback

The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:

  • “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
  • “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
  • “Very well organized! A great opportunity to see all French MDPI partners and editors.”

Program Highlights:

Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:

  • MDPI Overview and France Collaboration – Stefan Tochev (CEO)
  • MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
  • Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
  • AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
  • Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
  • Closing Remarks – Stefan Tochev
  • Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan

MDPI & France: Facts and Figures

  • With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
  • As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
  • As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
  • Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
  • In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.

Special thanks to our colleagues from Romanian offices for organizing this successful event.

Closing Thoughts

Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award

As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.

A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.

About the Tu Youyou Award
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honour the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award recognizing exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Stefan Tochev
Chief Executive Officer
MDPI AG

1 July 2025
Meet Us at the CRS 2025 Annual Meeting and Exposition, 14–18 July 2025, Philadelphia, USA


Conference: The CRS 2025 Annual Meeting and Exposition
Date: 14–18 July 2025
Location: Philadelphia, USA

This conference will be the 52nd annual conference of the Controlled Release Society. The annual CRS conference is the most important conference in the pharmaceutics field. The main topics of the conference include nanomedicine and nanoscale delivery, immuno delivery, oral delivery, skin and mucosal delivery, ocular delivery, bioengineering, gene delivery and gene editing, alternative methods to animal testing, long-acting drug delivery formulations, delivery to the nervous system, artificial intelligence, and predictive models in pharmaceutical technologies.

The following open access journals will be represented at the event:

If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person at booth #202 and answering any questions you may have. For more information about the conference, please visit the following website: https://crs2025annualmeeting.eventscribe.net.

28 June 2025
Meet Us at the 17th Academic Conference of the Chinese Pharmacological Society, 22–26 July 2025, Xiong An, China


Conference:
The 17th Academic Conference of the Chinese Pharmacological Society

Date: 22–26 July 2025

Location: Xiong An, China

MDPI will be attending the 17th Academic Conference of the Chinese Pharmacological Society as an exhibitor, which will be held from 22 to 26 July 2025. We welcome researchers from diverse backgrounds to attend and share their latest ideas with us.

The year 2025 marks the 40th anniversary of the establishment of the Chinese Pharmacological Society. We are pleased to attend the conference, which will systematically summarize the experience of the Chinese Pharmacological Society’s construction and development over the past 40 years. The 17th Academic Conference of the Chinese Pharmacological Society serves as an interdisciplinary forum for the prompt exchange of recent achievements, experiences, theories, technologies, and methods in China's pharmacology research domain, in addition to new drug development and related fields, The conference will promote the innovative development of China's pharmacology research and new drug development on a longer-term basis. Your participation will significantly contribute to the medical discourse and enhance the conference’s impact within the pharmacological field.

The following MDPI journals will be represented at the conference:

If you are planning to attend the above conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information about the conference, please visit the following website: https://mm.sciconf.cn/cn/web/index/29613?pc=1.

26 June 2025
Meet Us at the 2nd International Congress of Advanced Medical Engineering (I-CAME2025), 25–27 June 2025, Shangai, China


We are pleased to invite you to attend the 2nd International Congress of Advanced Medical Engineering (I-CAME2025), taking place in Shanghai, China, from 25 to 27 June 2025.

The aim of this conference is to provide an interdisciplinary platform for scientists, engineers, and clinicians to accelerate translational breakthroughs in patient health and well-being. Topics relating to biomaterials, stem cell biology, bioreactor and 3D scaffold technology, decellularized tissue, and advances in surgical techniques are just a few of the areas the conference hopes to address.

Important Dates:

  • Abstract deadline: 15 April 2025;
  • Acceptance confirmation deadline: 20 April 2025;
  • ZRX awards e-poster deadline: 20 April 2025;
  • Early bird registration deadline: 30 May 2025;
  • Fuyue Hotel Shanghai booking deadline: 10 June 2025;
  • Onsite registration: 25 June 2025;
  • Conference dates: 25–27 June 2025.

For more information about the conference, please visit the following website: http://www.i-came2025.com/.

25 June 2025
Biomedicines Receives an Updated Impact Factor of 3.9


We are pleased to share that Biomedicines (ISSN: 2227-9059) was awarded an updated Impact Factor of 3.9 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Biomedicines ranks in Q1 (88 among 352 titles) in the “Pharmacology & Pharmacy” category.

The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years.

To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information.

The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.

Back to TopTop